JPRN-jRCT2031200269招募中3 期
Extension study of P1101 in Japanese patients who have completed phase 2 single arm study in polycythemia vera (PV) patients (Study A19-201) or phase 3 study in essential thrombocythemia (ET) patients (Study P1101 ET)
Kawase Hiroaki0 个研究点目标入组 67 人开始时间: 2020年12月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 67
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients who have completed the 52-week P1101 treatment duration in Study A19-201 and are considered by the investigator or subinvestigator to be eligible for participation in this study
- •2. Patients who have completed the follow-up/end-of-study visit in Study P1101 ET and are considered by the investigator or subinvestigator to be eligible for participation in this study
- •3. Patients who have given written informed consent to participate in this study
排除标准
- •1. Patients who are considered by the investigator or subinvestigator to be ineligible for continued treatment with P1101 or switch from anagrelide to P1101
研究者
相似试验
招募中
3 期
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsPolycythemia Vera (PV)NCT04655092PharmaEssentia Japan K.K.67
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33
已完成
1 期
EDO-S101 Phase I study for Japanese patients with relapsed/refractory hematological malignancyJPRN-jRCT2080224049MUNDIPHARMA K.K.15
终止
2 期
A Clinical Phase 2 Study of E6011 in Japanese Subjects with Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic AcidPrimary Biliary CholangitisJPRN-jRCT2080223460EA Pharma Co.,Ltd.80
进行中（未招募）
1 期
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type IMucopolysaccharidosis IJPRN-jRCT2051210040Kawashima Satoshi14